Cerebrolysin
FPE 1070 · Brain-derived peptide preparation
A cocktail of brain-derived peptides used clinically across 50+ countries. The West mostly ignores it. That might be a mistake.
Educational content only. Not medical advice. This compound may be regulated in your jurisdiction. Consult a healthcare professional.
01 What is Cerebrolysin?
Cerebrolysin is not a single compound — it is a mixture of low-molecular-weight peptides and free amino acids derived from purified pig brain proteins. Developed in Austria by EVER Neuro Pharma, it has been used clinically for over 40 years in more than 50 countries for stroke recovery, traumatic brain injury, dementia, and cognitive decline. It is genuinely one of the most widely-used neuroprotective treatments globally — just not in the UK or US. The Western medical establishment has been slow to adopt it, partly because its multi-component nature makes it difficult to study with the reductionist approach preferred by the FDA (one molecule, one mechanism, one indication). But the clinical data from Asia, Eastern Europe, and South America is substantial — over 200 clinical studies involving more than 50,000 patients. Biohackers use it for cognitive enhancement, brain injury recovery, and neuroprotection. The injectable route (IM or IV) means it is not a casual supplement — this is a serious intervention.
02 How Does It Work?
Cerebrolysin contains peptides that mimic the activity of endogenous neurotrophic factors — BDNF, NGF, CNTF, and GDNF. These peptide fragments are small enough to cross the blood-brain barrier (unlike full-size neurotrophins) and activate the same downstream signalling cascades. The result is multi-modal neuroprotection: reduced excitotoxicity, decreased oxidative stress, inhibition of calpain (which damages neurons after injury), promotion of neurogenesis, and enhancement of synaptic plasticity. It is essentially providing your brain with the same repair signals it produces naturally, but in therapeutic concentrations.
03 What Does The Research Say?
Strong clinical evidence from human trials.
Over 200 clinical studies. A Cochrane review exists (though notes methodology concerns in many studies). Large trials in stroke patients (CASTA trial: 1,070 patients) showed improved neurological outcomes. Studies in Alzheimer's patients show cognitive improvement comparable to donepezil. TBI studies show accelerated recovery. Criticisms: many studies are industry-sponsored, methodology varies, and results from Asian/Eastern European trials may not perfectly translate to Western populations. The FDA has not approved it, partly because the multi-peptide composition makes the standard approval pathway impractical. But the sheer volume of positive data across multiple indications and countries is difficult to dismiss entirely.
04 Reported Dosages
Research literature dosages only. NOT medical recommendations. Always consult a healthcare professional.
Clinical protocols: 10-30ml IV infusion daily for 10-20 day courses. Repeated 2-4 times per year. IM injection: 5-10ml daily for similar course lengths. Community protocols: 5-10ml IM daily for 10-20 days. MUST be administered by injection (not orally bioavailable). These are clinical dosages from countries where it is approved.
05 Side Effects & Risks
Generally well-tolerated in clinical studies. Injection site pain, occasional dizziness, mild agitation, headache. Rare: allergic reactions (contains animal-derived proteins). Vertigo and hot flushes reported infrequently. Contraindicated in epilepsy and severe renal impairment.
06 Legal Status
Not approved by MHRA. Not readily available.
Not FDA-approved. Available through some compounding pharmacies and international sources.
Approved in Austria and several EU countries as a prescription medication.
Not TGA-approved. Available through Special Access Scheme.
Goal Guides for Cerebrolysin
Explore how Cerebrolysin may support specific health goals: